alzheimer's disease and the β amyloid peptide an important role in AD - Aβ Amyloid-β peptide appears to play a central role in the pathology of Alzheimer disease Alzheimer's Disease and the β-Amyloid Peptide: Unraveling the Connection

Microglial mechanisms driveamyloid βclearance in immunized patients withalzheimer's disease Alzheimer's disease (AD), the most common cause of dementia, is a complex neurodegenerative disorder characterized by progressive cognitive decline.作者：X Sun·2015·被引用次数：434—Theamyloid β peptide(Aβ) is a critical initiator that triggers the progression ofAlzheimer's Disease(AD) via accumulation and aggregation. A central focus in understanding its pathogenesis is the role of the β-amyloid peptide (Aβ). Decades of research have consistently pointed to the production and deposition of this peptide as a primary driver of the disease. This article delves into the intricate relationship between Alzheimer's disease and the β-amyloid peptide, exploring its formation, aggregation, and the resulting pathological consequences.The Amyloid-β Pathway in Alzheimer's Disease

The story of Alzheimer's disease and amyloid begins with the amyloid precursor protein (APP). This protein, normally processed through a non-amyloidogenic pathway, can also undergo an alternative, amyloidogenic pathway. In this process, APP is cleaved by specific enzymes, leading to the generation of amyloid beta peptides. These peptides are typically composed of 36 to 43 amino acids and are the main component of amyloid plaques found in the brains of individuals with AD.The primary component ofamyloidplaques in the brain and cerebrovasculature of AD and Down's Syndrome patients was first identified as the ~4 kDa Aβpeptide,.

A critical aspect of Aβ peptide formation is the ratio of different isoforms, particularly Aβ40 and Aβ42Elevated Plasma β-Amyloid Peptide Aβ42 Levels, Incident .... While both are produced, Aβ42 is considered more prone to aggregation and is therefore more strongly implicated in AD pathology. Studies have shown that levels of total Aβx-40 and Aβx-42 were elevated early in dementia, with levels of both peptides strongly correlated with cognitive decline. This elevation suggests that an imbalance in production or clearance mechanisms contributes to the disease processThe primary component ofamyloidplaques in the brain and cerebrovasculature of AD and Down's Syndrome patients was first identified as the ~4 kDa Aβpeptide,..

The aggregation of Aβ peptides is a hallmark of Alzheimer's diseaseThe Amyloid-β Pathway in Alzheimer's Disease. These peptides can rapidly aggregate to form fibrils that deposit extracellularly, forming beta-amyloid plaques.2023年11月22日—Beta-amyloid (Aβ) playsan important role in ADpathology, and the Aβ42/40 peptide ratio is a good indicator for amyloid deposition. In addition ... While the presence of amyloid plaques is a defining characteristic of AD, the precise role of these aggregates in neuronal dysfunction and death is still a subject of ongoing research. However, current models primarily implicate amyloid β-peptides (Aβ) in the disease's progression, associating them with various cellular dysfunctions. The accumulation and deposition of these Aβ peptide aggregates in the brain are central to the "Aβ hypothesis" of Alzheimer's disease.

Beyond extracellular plaques, evidence also suggests that amyloid precursor protein is processed into amyloid beta peptides that can accumulate both inside and outside neuronal cells. The formation of these amyloid plaques is a key event, and the amyloid-β (Aβ) pathway is considered to be at the center of Alzheimer's disease pathophysiology. Furthermore, Alzheimer disease (AD) is defined by the presence of extracellular β-amyloid (Aβ) plaques and intracellular tau protein-containing neurofibrillary tangles (NFTs).

Research has also explored the potential physiological roles of monomeric amyloid-β. While its pathological role in aggregation is well-established, some studies suggest that Aβ peptide might normally function in the innate immune system, acting as an AMP (antimicrobial peptide). However, dysregulation of this function could contribute to the inflammatory processes observed in Alzheimer's disease.

The significance of Aβ peptide in AD pathology is underscored by the development of diagnostic tools. For instance, the Aβ42/40 peptide ratio is considered a good indicator for amyloid deposition, and new plasma LC-MS/MS assays are being developed to quantify these levels, offering potential for early detection. Indeed, increased amyloid beta-peptide deposition in cerebral cortex has been linked to the disease, and elevated plasma β-amyloid peptide Aβ42 levels have been associated with incident AD.

Understanding the Alzheimer's disease mechanism involving β-amyloid is crucial for developing effective therapeutic strategies. Amyloid β-based therapy for Alzheimer's disease is a major area of research, aiming to reduce the production, aggregation, or promote the clearance of these peptidesAmyloid betadenotespeptidesof 36–43 amino acids that are the main component of theamyloidplaques found in the brains of people withAlzheimer's disease.... While the field faces challenges and controversies, the central role of the β-amyloid peptide in the progression of Alzheimer's disease remains a cornerstone of our current understanding. The ongoing exploration of the amyloid cascade, from beta peptide generation to plaque formation, continues to shed light on this devastating condition.